Mostrar el registro sencillo del ítem

dc.contributor.authorTall, Alan R
dc.contributor.authorFuster, Jose J. 
dc.date.accessioned2022-12-22T14:18:07Z
dc.date.available2022-12-22T14:18:07Z
dc.date.issued2022-02
dc.identifier.citationNat Cardiovasc Res. 2022 Feb;1(2):116-124. Epub 2022 Feb 7.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15400
dc.description.abstractClonal hematopoiesis arises from somatic mutations that provide a fitness advantage to hematopoietic stem cells and the outgrowth of clones of blood cells. Clonal hematopoiesis commonly involves mutations in genes that are involved in epigenetic modifications, signaling and DNA damage repair. Clonal hematopoiesis has emerged as a major independent risk factor in atherosclerotic cardiovascular disease, thrombosis and heart failure. Studies in mouse models of clonal hematopoiesis have shown an increase in atherosclerosis, thrombosis and heart failure, involving increased myeloid cell inflammatory responses and inflammasome activation. Although increased inflammatory responses have emerged as a common underlying principle, some recent studies indicate mutation-specific effects. The discovery of the association of clonal hematopoiesis with cardiovascular disease and the recent demonstration of benefit of anti-inflammatory treatments in human cardiovascular disease converge to suggest that anti-inflammatory treatments should be directed to individuals with clonal hematopoiesis. Such treatments could target specific inflammasomes, common downstream mediators such as IL-1β and IL-6, or mutations linked to clonal hematopoiesis.es_ES
dc.description.sponsorshipA.T. and J.J.F. are supported by a grant from the Leducq Foundation (TNE-18CVD04). A.T. is supported by NIH grant 155431. We thank M. A. Zuriaga for assistance with figure design.es_ES
dc.language.isoenges_ES
dc.publisherSpringer es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleClonal hematopoiesis in cardiovascular disease and therapeutic implications.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID36337911es_ES
dc.format.volume1es_ES
dc.format.number2es_ES
dc.format.page116es_ES
dc.identifier.doi10.1038/s44161-021-00015-3es_ES
dc.contributor.funderFondation Leducq es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2731-0590es_ES
dc.relation.publisherversiondoi: 10.1038/s44161-021-00015-3es_ES
dc.identifier.journalNature cardiovascular researches_ES
dc.repisalud.orgCNICCNIC::Fisiopatología Hematovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional